- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
DARA Biosciences Inc
+ Add to WatchlistDARA:US
0.6199 USD 0.0750 10.79%As of 11:30:21 ET on 10/03/2013.
Snapshot for DARA Biosciences Inc (DARA)
| Open: | 0.6900 | Day's Range: | 0.5826 - 0.6900 | Volume: | 663,998 |
|---|---|---|---|---|---|
| Previous Close: | 0.6949 | 52wk Range: | 0.4699 - 1.2000 | 1-Yr Rtn: | -40.84% |
Key Statistics for DARA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.4700 |
| Est. EPS (USD) (12/2013) | -0.3200 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 17.37 |
| Shares Outstanding (M) | 25.00 |
| 30 Day Average Volume | 271,001 |
| Price/Book (mrq) | 1.7092 |
| Price/Sale (ttm) | 88.0017 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Dividend Ex-Date | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DARA
Company Profile & Key Executives for DARA
DARA BioSciences, Inc. is a development stage pharmaceutical company. The Company acquires therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses on small molecules from late preclinical development through phase 2 clinical trials for neuropathic pain, metabolic diseases, and dermatological disorders.
| Christopher G ClementPresident/COO | David J DrutzCEO/Chief Medical Officer |
| David L TousleyChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
Advertisement
-
DARA News
-
Industry News
Advertisement
Sponsored Links
Advertisements
Rate this Page